RE: Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain

Breast. 2021 Dec:60:302. doi: 10.1016/j.breast.2021.10.003. Epub 2021 Oct 13.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / pathology
  • Female
  • Humans
  • Phthalazines / therapeutic use
  • Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use
  • Spain

Substances

  • Phthalazines
  • Poly(ADP-ribose) Polymerase Inhibitors
  • talazoparib